Presentations at the 9th AMR Conference and at ICDS 2024
Crestone had the opportunity to showcase its innovative research at the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia.
Knowledge Portal
Stay up to date with the latest news and information about our pipeline projects, novel antibiotics research, antimicrobial development efforts, and C. diff clinical trials.
Browse
Events
Browse
Press Releases
Browse
Information
Events
Press Releases
Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lancet Infectious Diseases
Phase 2 results, multi-omics gut microbiome data, and Phase 3 readiness milestones announced via Business Wire.
Information
CRS3123 Phase 2 Results Published in The Lancet Infectious Diseases
A landmark Phase 2 randomized controlled trial demonstrates the safety, tolerability, and promising efficacy of CRS3123 as a novel treatment for C. difficile infection.
Become a Part of Our Projects
Interested in helping further our research into novel antibiotics? We’d be thrilled to have your help, either as an investor or a team member.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.